Discussing the potential of WAINUA (eplontersen) as an FDA approved treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy.

Executed on:Mar 14, 2024 5:45 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: SUNY Downstate Medical CenterDirector of the Muscular Dystrophy Association Clinic and Associate Professor of Neurology at SUNY Downstate Medical Center.
Treats 8 patients with ATTR-PN, 15 patients for Friedreich’s Ataxia and 90 patients with myasthenia gravis.
Research Interests in HIV-related neuropathy, inflammatory myopathies and has a clinical specialty in Neuromuscular disease.

Interview Goal

On this call we will be speaking with a neurologist about AstraZeneca and Ionis’ WAINUA (eplontersen) and the Phase III NEURO-TTRansform results presented at 2023 AAN Annual Meeting of eplontersen in patients with ATTRv-PN.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.